John Wagner

John A. Wagner, M.D., Ph.D. oversees clinical investment and strategy at Koneksa. With more than 20 years of drug development experience, Dr. Wagner has led more than 150 first-in-human studies and has been instrumental bringing numerous blockbuster programs to market. Prior to joining Koneksa, John was CMO of Cygnal Therapeutics, held senior leadership roles at Takeda and Merck, and was a venture partner at Foresite Capital. In addition, John is Editor-in-Chief of Clinical and Translational Science and an executive committee member of the Foundation for the National Institutes of Health Biomarkers Consortium.